Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$54.4M
32M shares
52-week range
$1.18 – $3.21
25% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
2.56%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $15.2M | $25.4M | $18.1M | $29.6M | $19.6M |
| Cost of revenue | $8.2M | $14.5M | $10.2M | $16.3M | $10.7M |
| Gross profit | $7.1M | $10.8M | $7.9M | $13.3M | $8.9M |
| Gross margin | 46.3% | 42.7% | 43.6% | 44.9% | 45.4% |
| R&D | $0 | $0 | $0 | $29.6M | $19.6M |
| Operating income | −$4.2M | −$2.6M | −$13.0M | −$6.6M | −$8.6M |
| EBITDA | −$4.1M | −$2.2M | −$20.1M | −$11.5M | −$5.4M |
| Net income | −$4.0M | −$2.9M | −$20.9M | −$15.3M | −$7.6M |
| Net margin | -26.2% | -11.5% | -115.5% | -51.8% | -38.5% |
| EPS (diluted) | -0.33 | -0.16 | -1.48 | -0.85 | -0.29 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-0.51 | $-0.71–$-0.31 | 1 |
| 2027 | $23M | $-0.54 | $-0.74–$-0.33 | 1 |
| 2028 | $25M | $-0.59 | $-0.92–$-0.26 | 2 |
| 2029 | $13M | $-0.08 | $-0.11–$-0.05 | 1 |
Forward consensus · source: Financial Modeling Prep
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
www.spectral-ai.comNo one on the platform currently holds MDAI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 96,025 | $271.8K |
No one on the platform has traded MDAI yet.
| $109M |
| — |
| ICCMIceCure Medical Ltd | $5.26 | -11.74% | $12M | — |
| IPSCCentury Therapeutics, Inc. | $2.41 | +3.88% | $209M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 1.0× sales vs its 2.3× historical median P/S.
Fair value ≈ $3.96 · price $1.69 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$MDAI Oh please, pleazeee let that be acompained by a bet from Johhny No Commmuicatons to Shareholders with Polymarket on an MDAI ppr bump.
View on StockTwits ↗$MDAI Ah yes, never miss an opportunity to close red. After all… it’s an MDAI tradition!
View on StockTwits ↗$MDAI Thanks Corbett for the due diligence
View on StockTwits ↗$MDAI The CEO did speak about the business plan on the recent podcast. They intend to lease the machines, and BARDA funding is enough to put a unit in every burn center in the US. This is important because it means the initial take up of the machines will be low-friction for hospitals/trauma centers. Going into next year, as they focus on ulcers and other designations, they will not need to deploy more machines. They will simply be able to offer these features to current users and expand revenue with a very simple sales pitch. They are trying to build a wound assessment platform where they own the hardware, software, and data. If you look around and similar cases, this business model is incredibly valuable is executed. They will be priced closer to SaaS than a typical medical device company. This is also very enticing for acquisitions. All that to speak nothing of the DoD project in the background. I also found RGTI under $1. I don't have a day job. I like MDAI. Cheers. PT2
View on StockTwits ↗$MDAI I don't post often, but I've seen people confused about the price action over the last couple of weeks and I wanted to try and shed some light on both biotech as a whole and MDAI and their business plan with the DeepView deployment. First of all, I'm no expert, but I was in both ARDX and CHRS under $1. ARDX was a very similar situation MDAI finds itself in now. Waited for approval for their flagship, PA raising the entire way, only to fall off a cliff when the news came out that they received it. This story isn't unique to MDAI, and it's a very common exit point for many long term holders. Sure enough, randomly about 6 months after ADCOM, ARDX rose to meet and then exceed the median PTs. Not a single sale yet, and no news. The point I'm trying to make is that if you're long, it's better to focus on analyzing the business and not the price action at this stage. PT.1
View on StockTwits ↗$MDAI ended week on a slight positive note… rough days ahead before we hear anything meaningful by year end on deployment and BARDA funding based on milestones. Waiting on my 1.50 Range to back up the truck
View on StockTwits ↗$MDAI Me too. Still here, still bullish. A bit disappointed and growing impatient… however, I’m convinced that a little more patience will pay off. With FDA approval behind us, sales or buyout news could happen at any moment. Still holding all of my shares with the added benefit of paying Long Term Capital Gains Tax instead of Short Term when it comes time to sell.
View on StockTwits ↗$MDAI ... In the company press release on June 11th they did reiterate first commercial sales by the end of 2026. So that's only about 2 weeks ago.
View on StockTwits ↗$MDAI must watch this YouTube about fraud. It will be easy to catch fraud with this AI. Duplicate patient days etc... or non existent patients. Watch skin graft fraud, costing 1 million per fake patient. https://youtu.be/MHVzNtryMYE?is=JtndmEBU_AbdQAUe Use your imagination how much this technology will save USA taxpayers and true patients.
View on StockTwits ↗$MDAI When will we first learn of new orders? You’d think some of these medical providers now using Deep View systems on a trial bases would be ready to buy a few, if they can see the real benefits to patients and their budgets. Very strange this long silence.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.